Monte Rosa Therapeutics (GLUE) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Monte Rosa Therapeutics
Is Monte Rosa Therapeutics a buy right now? The alternative data says hold. This GLUE stock analysis is built on the 25+ alternative data signals AltIndex tracks on Monte Rosa Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 50/100: a Hold. The stock trades at $9.87 with a $876M market cap.
The soft spots over the past 90 days: revenue down 50.0% YoY to $10M. The rest of the signal set is holding steady, which keeps GLUE at a hold rather than a sell.
GLUE’s broader alt-data profile also covers job postings (31 open roles), headcount (227 employees, according to LinkedIn), web traffic (11K monthly visits), and Reddit mentions (6 a day). Every signal links to its own page with full history, the GLUE technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on GLUE is just below.
Monte Rosa Therapeutics AI Stock Analysis
Monte Rosa Therapeutics is a biotechnology company focused on discovering and developing precision medicines that target protein degradation pathways. The company aims to design molecular glues that can treat genetically defined diseases by eliminating disease-causing proteins.
Analysis generated September 29, 2026.
Recent Monte Rosa Therapeutics Stock Alerts
|
Monte Rosa Therapeutics | October 2 Price is down by -6.2% in the last 24h. |
|
Monte Rosa Therapeutics | October 1 Price is down by -6.2% in the last 24h. |
|
Monte Rosa Therapeutics | September 23 Price is down by -6% in the last 24h. |
|
Monte Rosa Therapeutics | August 28 Price is down by -6.3% in the last 24h. |
Monte Rosa Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 11K | N/A | |
| Job Posts | 31 | N/A | |
| LinkedIn Employees | 227 | N/A | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 6 | N/A | |
| X Mentions | 1 | N/A | |
| Stocktwits Mentions | 45 | 221.4% | |
| News Mentions | 1 | N/A | |
| Stocktwits Subscribers | 1K | N/A |
About Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.
| Price | $9.87 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $876M |
| Year Range | $8 – $25 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Monte Rosa Therapeutics News
View more → |
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 StudyOctober 6 - Biztoc.com |
 |
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trialSeptember 28 - Nature.com |
See Monte Rosa Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for GLUE, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEMonte Rosa Therapeutics Earnings & Financial Performance
View all earnings →Monte Rosa Therapeutics Insider Trading Activity
View all →| Warmuth Markus filed to sell 585,038 shares at $0.0. Jul 16 '26 |
| Champoux Jennifer filed to sell 62,371 shares at $0.0. Jul 15 '26 |
| Townson Sharon filed to sell 67,845 shares at $0.0. Jul 6 '26 |
| Townson Sharon filed to sell 68,245 shares at $0.0. Jul 6 '26 |
| Janku Filip filed to sell 60,612 shares at $0.0. Jun 30 '26 |
Monte Rosa Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Monte Rosa Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
ArdelyxARDX |
$3.31 2.4% | $875M | 52 |
 |
Arbutus BiopharmaABUS |
$4.48 4.1% | $882M | 46 |
 |
Theravance BiopharmaTBPH |
$17.03 0.0% | $884M | 44 |
 |
Corvus PharmaceuticalsCRVS |
$10.56 1.7% | $903M | 44 |
 |
Sana BiotechnologySANA |
$2.75 4.5% | $823M | 38 |
Explore Monte Rosa Therapeutics Data
Frequently Asked Questions: Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics has an AltIndex AI Score of 50/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
50/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Monte Rosa Therapeutics (GLUE) stock is $9.87 with a market cap of $876M.
As of today, Monte Rosa Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Monte Rosa Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Monte Rosa Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The GLUE stock price chart above shows Monte Rosa Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Monte Rosa Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Monte Rosa Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
